Neuroplasticity Biomarkers in Aphasia

Официальное название

Genetic and MRI Biomarkers of Neuroplasticity Predict Aphasia Recovery and Phenotypes

Обзор

Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity. The proposed work will evaluate genetic and neural network biological markers of neuroplasticity associated with variability in aphasia, with a future goal to improve prognostics and identify therapeutic targets to reduce the long-term burdens of aphasia.

Подробное описание

Aphasia is an acquired neurologic language disorder that is among the most challenging long-term disabilities for stroke survivors, often leading to social isolation and reduced quality of life. Recovery from aphasia relies on plasticity in residual brain networks. However, neuroplasticity varies substantially across individuals, making the presence, severity, and phenotype of language impairments challenging to predict. A vital step toward post-stroke precision medicine is identifying neuroplasticity-related biological markers that can improve prognostic models and targeted neurorehabilitation therapies for people with aphasia. The proposed research will test the central hypothesis that individual differences in neuroplasticity, measured through genetic polymorphisms and longitudinal neuroimaging connectivity biomarkers, will account for significant variance in post-stroke aphasia recovery. This 5-year project will include three specific aims. Aim 1 is to index spontaneous recovery by determining relationships between genetic biomarkers of plasticity, longitudinal neural network connectivity, and changes in language during sub-acute to chronic stroke recovery. Aim 2 is to identify genetic and MRI biomarkers predictive of chronic post-stroke aphasia severity and phenotypes. Aim 3 is to characterize genetic and MRI biomarkers associated with verbal learning variability in chronic aphasia. These data will support the development of a larger, multi-site R01 study to examine interactions between multiple biomarkers of neuroplasticity that inform longitudinal aphasia prognostics and treatment efficacy.

Вмешательства

• Поведенческое Pseudoword learning paradigm task
  Pseudoword learning is an experimental learning task by which participants view two novel objects (a target and a foil) and simultaneously hear an audio recording of the pseudoword name of one of the two objects. Participants must choose (via mouse click) which object corresponds to the word presented, immediately after which feedback is provided.

Первичные конечные точки

• Aphasia presence/severity [Срок оценки: 3 months, 6 months, 1 year post-stroke]
• Semantic processing [Срок оценки: At least 1 year post-stroke]
• Phonological processing [Срок оценки: At least 1 year post-stroke]
• Noun processing [Срок оценки: At least 1 year post-stroke]
• Verb processing [Срок оценки: At least 1 year post-stroke]
• Pseudoword learning [Срок оценки: At least 1 year post-stroke]
• Verbal learning [Срок оценки: At least 1 year post-stroke]

Вторичные конечные точки (1)

• Aphasia Communication Outcome Measure (ACOM) Score [Срок оценки: 1 year post-stroke]

Критерии участия

Критерии включения

• Ages 40-90
• Right-handed (prior to stroke)
• Proficient English speakers
• History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere.
• Presence of aphasia (Aims 2-3)
• Capacity to understand the nature of the study and provide informed consent
• Acute or subacute stroke at the time of Aim 1 enrollment; Stroke #12 months old (chronic) at the time of Aims 2-3 enrollment
• Medically stable

Критерии исключения

• History of significant medical or neurological disorder (other than stroke)
• History of significant or poorly controlled psychiatric disorders
• Current abuse of alcohol or drugs, prescription or otherwise
• Clinically significant and uncorrected vision or hearing loss
• Anything other than standard of care stroke treatment such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications or choles- terol-lowering agents, thrombolytics (e.g., tPA), anticoagulation agents such as Heparin, Warfarin/Coumadin

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Другое

Центры проведения

США · 1 центр

• UW School of Medicine and Public Health — Madison

Идентификаторы

NCT: NCT06471127 · 2023-1101 · 1K23DC021744 · A481800 · L&S/COMMUN SCI & DISORDERS · Protocol Version 6/18/2026

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗